TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Double Bond Pharmaceutical International AB (publ)
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
95
|
123
|
112 |
| Financial expenses |
478
|
352
|
0 |
| Earnings before taxes |
-619
|
-1,563
|
-1,362 |
| EBITDA |
-126
|
-1,193
|
-1,345 |
| Total assets |
1,075
|
1,045
|
1,383 |
| Current assets |
488
|
452
|
584 |
| Current liabilities |
727
|
563
|
298 |
| Equity capital |
348
|
483
|
1,085 |
| - share capital |
466
|
430
|
284 |
| Employees (average) |
9
|
10
|
10 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
32.4%
|
46.2%
|
78.5% |
| Turnover per employee |
11
|
12
|
11 |
| Profit as a percentage of turnover |
-651.6%
|
-1270.7%
|
-1216.1% |
| Return on assets (ROA) |
-13.1%
|
-115.9%
|
-98.5% |
| Current ratio |
67.1%
|
80.3%
|
196.0% |
| Return on equity (ROE) |
-177.9%
|
-323.6%
|
-125.5% |
| Change turnover |
-24
|
11
|
26 |
| Change turnover % |
-21%
|
10%
|
30% |
| Chg. No. of employees |
-1
|
0
|
0 |
| Chg. No. of employees % |
-10%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.